Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 1004

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 10
Chunk 1004
---
 Current
    Report on Form 8-K filed with the SEC on June 13, 2024).

    10.42
     
    Securities
    purchase agreement to purchase common stock and warrants (incorporated by reference to Exhibit 10.1 to the Current Report on Form
    8-K filed with the SEC on September 16, 2024).

    10.43
     
    Warrant to purchase common stock (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on September 16, 2024).

    10.44
     
    At-the-Market Sales Agreement, dated August 9, 2024, by and among INmune Bio Inc., RBC Capital Markets, LLC and BTIG, LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed on August 9, 2024).

    19.1
     
    Insider Trading Policy.*

    21.1
     
    Subsidiaries.*

    23.1
     
    Consent of Marcum LLP, independent registered public accounting firm.*

    31.1
     
    Certification of principal executive officer pursuant to Section 3.02 of the Sarbanes-Oxley Act of 2002.*

    31.2
     
    Certification of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

    32.1
     
    Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

    32.2

    Certification of principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

    97.1
     
    INmune
    Bio Policy for recovery of erroneously awarded compensation (incorporated by reference to Exhibit 97.1 to our Annual Report on Form
    10-K filed with the SEC on March 28, 2024).

    101.INS
     
    Inline
    XBRL Instance Document

    101.SCH
     
    Inline XBRL
    Taxonomy Extension Schema Document

    101.CAL
     
    Inline XBRL
    Taxonomy Extension Calculation Linkbase Document

    101.DEF